1. Home
  2. QFIN vs AGIO Comparison

QFIN vs AGIO Comparison

Compare QFIN & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Qifu Technology Inc.

QFIN

Qifu Technology Inc.

N/A

Current Price

$13.20

Market Cap

1.9B

Sector

Finance

ML Signal

N/A

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

N/A

Current Price

$28.48

Market Cap

1.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
QFIN
AGIO
Founded
2016
2007
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.6B
IPO Year
2018
2013

Fundamental Metrics

Financial Performance
Metric
QFIN
AGIO
Price
$13.20
$28.48
Analyst Decision
Strong Buy
Buy
Analyst Count
3
8
Target Price
$32.37
$37.63
AVG Volume (30 Days)
1.4M
642.1K
Earning Date
03-17-2026
04-30-2026
Dividend Yield
11.74%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$43,011,000.00
Revenue This Year
N/A
$75.68
Revenue Next Year
N/A
$167.63
P/E Ratio
$2.21
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.68
$22.24
52 Week High
$48.94
$46.00

Technical Indicators

Market Signals
Indicator
QFIN
AGIO
Relative Strength Index (RSI) 35.91 52.76
Support Level N/A $26.48
Resistance Level $15.46 $29.49
Average True Range (ATR) 0.54 0.92
MACD -0.04 -0.02
Stochastic Oscillator 22.86 69.02

Price Performance

Historical Comparison
QFIN
AGIO

About QFIN Qifu Technology Inc.

Qfin Holdings Inc Formerly Qifu Technology Inc is a Credit-Tech platform in China. It provides credit services more accessible and personalized to consumers and SMEs through Credit-Tech services to financial institutions, whereby it deploys its technology solutions to help financial institutions identify the diversified needs of consumers and SMEs, effectively access prospective borrowers that are creditworthy through multi-channels, enhance credit assessment on prospective borrowers, and manage credit risks and improve collection strategies and efficiency, among others.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

Share on Social Networks: